Pharmacy - Emergency Medicine Deep Dive Podcast

Clinical Management of Toxicological Seizures

In toxicology-induced status epilepticus, the clock starts ticking the moment first-line benzodiazepines fail. In this episode, we dive into the evolving evidence behind second-line therapies for benzodiazepine-refractory seizures, exploring why phenobarbital remains the best-supported option based on pharmacologic principles and animal data, while propofol emerges as a powerful rescue therapy in intubated patients. We also unpack the growing interest in levetiracetam, a medication praised for its favorable safety profile and minimal cardiorespiratory effects, but whose effectiveness in toxicologic seizures remains uncertain, particularly in stimulant-related cases highlighted by the ESETT subgroup analysis. Along the way, we examine why older agents like phenytoin may have little to no role in poisoned patients despite their historic use in seizure management. Through real-world clinical dilemmas, pharmacology insights, and emerging research, we explore how emergency clinicians navigate the race to stop seizures before irreversible neurological injury occurs. Whether you’re passionate about emergency medicine, toxicology, critical care, or neuropharmacology, this episode delivers a fascinating look at one of medicine’s highest-stakes treatment decisions.

Tenecteplase vs Alteplase: The Evolving Standard for Ischemic Stroke

Stroke thrombolysis is rapidly evolving and tenecteplase is emerging as one of the most exciting developments in acute ischemic stroke care. In this episode, we explore how a simple change from a one-hour infusion to a single IV bolus could transform stroke treatment workflows, improve transfer logistics, and potentially enhance early reperfusion in some patients. We unpack the science behind tenecteplase, review the landmark trials that challenged alteplase’s decades-long dominance, and discuss why clinicians around the world are paying close attention. From breakthrough studies in large vessel occlusion to major safety and non-inferiority trials, this episode highlights the evidence shaping modern stroke practice. This episode offers a practical and engaging overview of one of the biggest shifts in contemporary stroke care.

Pharmacological Priorities in Emergency Upper Gastrointestinal Bleeding

In this episode, we dive into the evolving evidence behind proton pump inhibitors (PPIs) in the management of nonvariceal upper gastrointestinal bleeding. While PPIs have long been considered standard early therapy, emerging data challenge whether starting treatment before endoscopy meaningfully improves major clinical outcomes such as mortality, surgery, or overall rebleeding rates. We explore how current evidence suggests the clearest benefit may be in patients with confirmed peptic ulcer bleeding, where PPIs can help reduce recurrent bleeding after endoscopic therapy. The episode also examines the growing shift away from continuous IV infusions toward intermittent dosing strategies, which appear similarly effective while potentially reducing cost and resource use. Join us as we unpack how evidence-based medicine is reshaping long-standing practices in emergency gastrointestinal care.

Is Ondansetron Really Dangerous? A Deep Dive into the Data

Ondansetron is a widely used antiemetic, but concerns have long circulated about its potential to prolong the QT interval and trigger dangerous arrhythmias like torsades de pointes. In this episode, we explore what the evidence actually shows, drawing on large-scale research including a review of over 32,000 surgical patients and a meta-analysis of 170 clinical trials. The data consistently suggests that at standard low doses, the risk of serious cardiac events is extremely low for most patients. We also unpack why reported adverse outcomes are often linked to underlying heart conditions rather than the medication itself, and how administration strategies like slower IV delivery or oral dosing may further reduce risk. Finally, we examine whether routine ECG monitoring is truly necessary in low-risk patients and what this means for everyday clinical practice.

Safety of Co-administering Olanzapine and Benzodiazepines for Acute Agitation

In this episode, we unpack the long-standing controversy around combining IM olanzapine with benzodiazepines like lorazepam in the management of acute agitation. While warnings from regulators such as the U.S. Food and Drug Administration have historically discouraged this pairing due to concerns about respiratory depression, we take a closer look at the data behind those risks. Emerging evidence suggests that adverse outcomes may be less common than previously feared, especially when doses are spaced appropriately and polypharmacy is minimized. We explore how this evolving literature challenges rigid institutional practices and what it means for bedside decision making in the ED. Tune in for a practical, evidence based approach to balancing safety and effectiveness in agitation management.